Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.

Abstract

Malignant gliomas remain among the most treatment-refractory tumors. Traditional upfront treatment regimens have incorporated nitrosurea-based chemotherapy. This strategy has evolved to include temozolomide-based approaches. Promising Phase I/II data with TMZ in the recurrent setting prompted a Phase III EORTC study of TMZ in combination with RT for… (More)

Topics

  • Presentations referencing similar topics